Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype

Epigenetics

Volumn 7, Issue 12, 2012, Pages 1413-1420

  Simpson, Natalie E ^a   Tryndyak, Volodymyr P ^a   Pogribna, Marta ^a   Beland, Frederick A ^a   Pogribny, Igor P ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Breast cancer; Gene expression; Glutamine metabolism; Histone modifications

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUTAMINASE; GLUTAMINE; HISTONE; HISTONE METHYLTRANSFERASE; MYC PROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MYB; TRANSCRIPTION FACTOR E2F1;

AMINO ACID METABOLISM; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL INVASION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MESENCHYME CELL; METABOLIC INHIBITION; PHENOTYPE; TRANSCRIPTION INITIATION; TUMOR GENE;

EID: 84870746218     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.22713     Document Type: Article

References (45)

1. Hitchler MJ, Domann FE. Metabolic defects provide a spark for the epigenetic switch in cancer. Free Radic Biol Med 2009; 47:115-27; PMID:19362589; http:// dx.doi.org/10.1016/j.freeradbiomed.2009.04.010
2. Teperino R, Schoonjans K, Auwerx J. Histone methyl transferases and demethylases; can they link metabolism and transcription? Cell Metab 2010; 12:321-7; PMID:20889125; http://dx.doi.org/10.1016/j. cmet.2010.09.004
3. Burgio G, Onorati MC, Corona DF. Chromatin remodeling regulation by small molecules and metabolites. Biochim Biophys Acta 2010; 1799:671-80; PMID:20493981; http://dx.doi.org/10.1016/j. bbagrm.2010.05.007
4. Rajendran P, Williams DE, Ho E, Dashwood RH. Metabolism as a key to histone deacetylase inhibition. Crit Rev Biochem Mol Biol 2011; 46:181-99; PMID:21599534; http://dx.doi.org/10.3109/1040923 8.2011.557713
5. Thangaraju M, Gopal E, Martin PM, Ananth S, Smith SB, Prasad PD, et al. SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res 2006; 66:11560-4; PMID:17178845; http://dx.doi.org/10.1158/0008-5472.CAN-06-1950
6. Ferreira LMR, Hebrant A, Dumont JE. Metabolic reprogramming of the tumor. Oncogene 2012; 31:3999-4011; PMID:22231450; http://dx.doi. org/10.1038/onc.2011.576
7. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-92; PMID:17320506; http://dx.doi. org/10.1016/j.cell.2007.01.029
8. Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev 2012; 22:50-5; PMID:22402447; http://dx.doi.org/10.1016/j. gde.2012.02.008
9. Simpson NE, Tryndyak VP, Beland FA, Pogribny IP. An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression. Breast Cancer Res Treat 2012; 133:959-68; PMID:22101407; http:// dx.doi.org/10.1007/s10549-011-1871-x
10. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010; 29:313-24; PMID:19881548; http://dx.doi.org/10.1038/onc.2009.358
11. Erickson JW, Cerione RA. Glutaminase: a hot spot for regulation of cancer cell metabolism? Oncotarget 2010; 1:734-40; PMID:21234284
12. Daye D, Wellen KE. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol 2012; 23:362-9; PMID:22349059; http://dx.doi.org/10.1016/j. semcdb.2012.02.002
13. Wang J-B, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010; 18:207-19; PMID:20832749; http://dx.doi.org/10.1016/j.ccr.2010.08.009
14. Asiago VM, Alvarado LZ, Shanaiah N, Gowda GA, Owusu-Sarfo K, Ballas RA, et al. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res 2010; 70:8309-18; PMID:20959483; http://dx.doi.org/10.1158/0008-5472.CAN-10-1319
15. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009; 324:1076-80; PMID:19461003; http://dx.doi. org/10.1126/science.1164097
16. Katt WP, Ramachandran S, Erickson JW, Cerione RA. Dibenzophenanthridines as inhibitors of glutaminase C and cancer cell proliferation. Mol Cancer Ther 2012; 11:1269-78; PMID:22496480; http://dx.doi. org/10.1158/1535-7163.MCT-11-0942
17. Steward MM, Lee J-S, O'Donovan A, Wyatt M, Bernstein BE, Shilatifard A. Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes. Nat Struct Mol Biol 2006; 13:852-4; PMID:16892064; http://dx.doi.org/10.1038/ nsmb1131
18. Tate CM, Lee JH, Skalnik DG. CXXC finger protein 1 restricts the Setd1A histone H3K4 methyltransferase complex to euchromatin. FEBS J 2010; 277:210-23; PMID:19951360; http://dx.doi.org/10.1111/j.1742-4658.2009.07475.x
19. Robin P, Fritsch L, Philipot O, Svinarchuk F, Ait-Si-Ali S. Post-translational modifications of histones H3 and H4 associated with the histone methyltransferases Suv39h1 and G9a. Genome Biol 2007; 8:R270; PMID:18096052; http://dx.doi.org/10.1186/gb-2007-8-12-r270
20. Vaquero A, Sternglanz R, Reinberg D. NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs. Oncogene 2007; 26:5505-20; PMID:17694090; http://dx.doi.org/10.1038/ sj.onc.1210617
21. Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010; 70:8981-7; PMID:21045145; http://dx.doi.org/10.1158/0008-5472.CAN-10-1666
22. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010; 330:1340-4; PMID:21127244; http://dx.doi.org/10.1126/science. 1193494
23. Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001; 61:4892-900; PMID:11406568
24. Zhang M, Guo R, Zhai Y, Yang D. LIGHT sensitizes IFNgamma-mediated apoptosis of MDAMB-231 breast cancer cells leading to down-regulation of anti-apoptosis Bcl-2 family members. Cancer Lett 2003; 195:201-10; PMID:12767529; http://dx.doi. org/10.1016/S0304-3835(03)00148-4
25. Carbone GM, Napoli S, Valentini A, Cavalli F, Watson DK, Catapano CV. Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucleic Acids Res 2004; 32:4358-67; PMID:15314206; http:// dx.doi.org/10.1093/nar/gkh744
26. Dubská L, Andera L, Sheard MA. HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAILinduced apoptosis. FEBS Lett 2005; 579:4149-58; PMID:16023111; http://dx.doi.org/10.1016/j.febslet. 2005.06.047
27. Toker A, Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res 2006; 66:3963-6; PMID:16618711; http://dx.doi.org/10.1158/0008-5472.CAN-06-0743
28. Park EJ, Min HY, Chung HJ, Hong JY, Kang YJ, Hung TM, et al. Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells. Cancer Lett 2009; 277:133-40; PMID:19135778; http://dx.doi.org/10.1016/j.canlet. 2008.11.029
29. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011; 11:558-72; PMID:21734724; http://dx.doi.org/10.1038/nrc3090
30. Lin Y, Cui H, Xu H, Yue L, Xu H, Jiang L, et al. Jolkinolide B induces apoptosis in MDA-MB-231 cells through inhibition of the PI3K/Akt signaling pathway. Oncol Rep 2012; 27:1976-80; PMID:22426554
31. Haas-Kogan DA, Kogan SC, Levi D, Dazin P, T'Ang A, Fung YK, et al. Inhibition of apoptosis by the retinoblastoma gene product. EMBO J 1995; 14:461-72; PMID:7859736
32. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444:61-6; PMID:17080083; http://dx.doi.org/10.1038/nature05194
33. Tryndyak VP, Beland FA, Pogribny IP. E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 2010; 126:2575-83; PMID:19839049
34. Zhang Y, Pu X, Shi M, Chen L, Qian L, Song Y, et al. c-Jun, a crucial molecule in metastasis of breast cancer and potential target for biotherapy. Oncol Rep 2007; 18:1207-12; PMID:17914574
35. Engelmann D, Pützer BM. The dark side of E2F1: in transit beyond apoptosis. Cancer Res 2012; 72:571-5; PMID:22298593; http://dx.doi.org/10.1158/0008-5472.CAN-11-2575
36. Kwon MJ, Kim SS, Choi YL, Jung HS, Balch C, Kim SH, et al. Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications. Carcinogenesis 2010; 31:974-83; PMID:20053926; http://dx.doi. org/10.1093/carcin/bgp336
37. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 2012; 13:343-57; PMID:22473383; http://dx.doi. org/10.1038/nrg3173
38. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128:693-705; PMID:17320507; http://dx.doi.org/10.1016/j.cell.2007.02.005
39. Sims RJ, Reinberg D. Histone H3 Lys 4 methylation: caught in a bind? Genes Dev 2006; 20:2779-86; PMID:17043307; http://dx.doi.org/10.1101/ gad.1468206
40. Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 2012; 13:297-311; PMID:22473470
41. Lüscher-Firzlaff J, Gawlista I, Vervoorts J, Kapelle K, Braunschweig T, Walsemann G, et al. The human trithorax protein hASH2 functions as an oncoprotein. Cancer Res 2008; 68:749-58; PMID:18245475; http://dx.doi.org/10.1158/0008-5472.CAN-07-3158
42. Kassis ES, Zhao M, Hong JA, Chen GA, Nguyen DM, Schrump DS. Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells. J Thorac Cardiovasc Surg 2006; 131:298-306; PMID:16434257; http://dx.doi.org/10.1016/j.jtcvs.2005.05.022
43. Lee J-H, You J, Dobrota E, Skalnik DG. Identification and characterization of a novel human PP1 phosphatase complex. J Biol Chem 2010; 285:24466-76; PMID:20516061; http://dx.doi.org/10.1074/jbc. M110.109801
44. Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Lüscher B, et al. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci U S A 2012; 109:E187-96; PMID:22190494; http://dx.doi.org/10.1073/ pnas.1105304109
45. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C method. Nat Protoc 2008; 3:1101-8; PMID:18546601; http://dx.doi. org/10.1038/nprot.2008.73